ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
1
views
9
references
Top references
cited by
0
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,743
similar
All similar
Record
: found
Abstract
: not found
Book Chapter
: not found
Encyclopedia of Biopharmaceutical Statistics, Second edition
Hypothesis Testing
other
Author(s):
Devan Mehrotra
,
Ivan Chan
Publication date
(Online):
April 08 2013
Publisher:
CRC Press
Read this book at
Publisher
Further versions
Buy book
Review
Review book
Invite someone to review
Bookmark
Cite as...
There is no author summary for this book yet. Authors can add summaries to their books on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
HIV Self-Testing
Most cited references
9
Record
: found
Abstract
: not found
Article
: not found
Multiparameter Hypothesis Testing and Acceptance Sampling
Roger L. Berger
(1982)
0
comments
Cited
44
times
– based on
0
reviews
Review now
Record
: found
Abstract
: not found
Article
: not found
Statistical Tests
K Fisher
(1935)
0
comments
Cited
20
times
– based on
0
reviews
Review now
Record
: found
Abstract
: not found
Book
: not found
D.V. A statistical paradox. Biometrika
B. JONES
(1957)
0
comments
Cited
1
times
– based on
0
reviews
All references
Author and book information
Book Chapter
Publication date (Print):
June 04 2003
Publication date (Online):
April 08 2013
Pages
: 433-436
DOI:
10.1201/b14760-64
SO-VID:
03e4f23c-1da7-4f35-a515-61ce8f17ed81
History
Data availability:
Comments
Comment on this book
Sign in to comment
Book chapters
pp. 1
Acceptance Sampling
pp. 9
Active Control Trials
pp. 16
Adaptive Survival Trials
pp. 18
Adjustment for Covariates
pp. 22
Adverse Event Reporting
pp. 28
Ames Test
pp. 36
Analysis of Heritability
pp. 42
Analysis of Variance
pp. 55
Assay Development
pp. 63
Assay Validation
pp. 72
Bayesian Statistics
pp. 80
Bioassay
pp. 83
Bioavailability and Bioequivalence
pp. 89
Biologics
pp. 100
Biopharmaceutics
pp. 121
Blinding
pp. 127
Bootstrap, The
pp. 133
Bracketing Design
pp. 134
Bridging Studies
pp. 139
Calibration
pp. 147
Canadian Health Products and Food Branch (HPFB) and Therapeutic Products Directorate (TPD)
pp. 152
Cancer Trials
pp. 160
Carcinogenicity Studies of Pharmaceuticals
pp. 175
Carry-Forward Analysis
pp. 181
Clinical Data Management
pp. 189
Clinical Endpoint
pp. 193
Clinical Pharmacology
pp. 196
Clinical Trial Process
pp. 200
Clinical Trial Simulation
pp. 202
Clinical Trials
pp. 210
Combination Drug Clinical Trial
pp. 214
Comparing Variabilities in Clinical Research
pp. 231
Confidence Interval and Hypothesis Testing
pp. 235
Confounding and Interaction
pp. 241
Content Uniformity
pp. 244
Contract Research Organization (CRO)
pp. 249
Cost-Effectiveness Analysis
pp. 255
Crossover Design
pp. 263
Cutoff Designs
pp. 270
Data Mining and Biopharmaceutical Research
pp. 277
Data Monitoring Committees (DMC)
pp. 288
Diagnostic Imaging
pp. 295
Dose Proportionality
pp. 298
Dose Response Analysis in Clinical Trials
pp. 304
Dose Response Study Design
pp. 311
Dropout
pp. 317
Drug Development
pp. 324
Enrichment Design
pp. 327
Equivalence Trials
pp. 333
Ethnic Factors
pp. 336
Expiration Dating Period
pp. 343
Exploratory Factor Analysis
pp. 349
Extra Variation Models
pp. 364
Factorial Designs
pp. 379
Food and Drug Administration
pp. 386
Generalizability Probability in Clinical Research
pp. 390
Generalized Estimating Equation
pp. 397
Global Database and System
pp. 403
Good Clinical Practice
pp. 410
Good Programming Practice
pp. 417
Good Statistics Practice
pp. 423
Group Sequential Methods
pp. 433
Hypothesis Testing
pp. 437
Imputation in Clinical Research
pp. 443
Imputation with Item Nonrespondents
pp. 449
In Vitro Bioequivalence Testing
pp. 456
In Vitro Dissolution Profile Comparison
pp. 463
In Vitro Micronucleus Test
pp. 468
Individual Bioequivalence
pp. 476
Instrument Development and Validation
pp. 486
Integrated Summary Report
pp. 490
Intention-to-Treat Analyses (ITT)
pp. 494
Interactive Voice Randomization System (IVRS)
pp. 502
Interim Analysis
pp. 508
Intemational Conference on Harmonization (ICH)
pp. 512
Investigating Quality-of-Life in Clinical Trials
pp. 518
Kaplan–Meier Estimator
pp. 524
Laboratory Analyses
pp. 532
Lilly Reference Ranges
pp. 548
Logistic Regression
pp. 554
Maximum Tolerable Dose for Cancer Chemotherapy
pp. 561
Measuring Agreement
pp. 568
MedDRA and Its Impact on Pharmaceutical Development
pp. 574
Medical Devices
pp. 586
Meta-Analysis of Therapeutic Trials
pp. 599
Microarray Gene Expression
pp. 614
Minimization Procedure
pp. 619
Minimum Effective Dose
pp. 622
Ministry of Health, Labour and Welfare and Pharmaceutical Administration in Japan
pp. 630
Mixed Effects Models
pp. 635
Multicenter Trials
pp. 639
Multinational Clinical Trial
pp. 647
Multiple Comparisons
pp. 652
Multiple-Dose Bioequivalence Studies
pp. 656
Multiple Endpoints
pp. 666
Multiplicity in Clinical Trials
pp. 674
Noninferiority Analysis in Active Controlled Clinical Trials
pp. 678
Odds Ratio
pp. 685
P-Values
pp. 696
P-Values, Evidence and Multiplicity Considerations for Controlled Clinical Trials
pp. 707
Parallel Design
pp. 712
Patient Compliance
pp. 718
Pharmacodynamic Issues
pp. 727
Pharmacodynamics with Covariates
pp. 740
Pharmacodynamics with No Covariates
pp. 749
Pharmacoeconomics
pp. 764
Placebo Effect
pp. 769
Population Bioequivalence
pp. 776
Postmarketing Adverse Drug Event Signaling
pp. 790
Postmarketing Surveillance
pp. 798
Power
pp. 800
Process Validation
pp. 816
Proportional Hazards Regression Model
pp. 824
Protocol Development
pp. 828
Randomization
pp. 833
Release Targets
pp. 838
Reproducibility Probability in Clinical Research
pp. 850
Reproductive/Developmental Studies
pp. 858
Response Surface Methodology
pp. 870
Robust Analysis for Crossover Design
pp. 884
ROC Curve
pp. 892
Sample Size Calculation for Survival Data
pp. 899
Sample Size Determination
pp. 915
Sample Size Re-estimation Based on Observed Treatment Difference
pp. 920
Screening Design
pp. 921
Selection of Control in Clinical Trials
pp. 927
Specifications
pp. 929
Stability Analysis for Frozen Drug Products
pp. 934
Stability Matrix Designs
pp. 940
Statistical Principles for Clinical Trials
pp. 945
Statistical Process Control
pp. 954
Statistical Significance
pp. 959
Subgroup Analysis
pp. 967
Surrogate Endpoint
pp. 972
Survival Analysis
pp. 977
Therapeutic Equivalence
pp. 983
Titration Design
pp. 988
Toxicological Studies
pp. 1003
USP Tests
pp. 1005
Vaccine Clinical Trials
pp. 1023
Validity of LOCF
pp. 1031
Index
Similar content
1,743
Parkinson's disease: a dual‐hit hypothesis
Authors:
C Hawkes
,
K Del Tredici
,
H Braak
Sharper bounds for the error in the prime number theorem assuming the Riemann Hypothesis
Authors:
Ethan Simpson Lee
,
Paweł Nosal
Advancing the pH hypothesis of negative feedback to photoreceptors: sources of protons and a role for bicarbonate in feedback
Authors:
Michael Country
See all similar